Yidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops

Reuters
Sep 23
<a href="https://laohu8.com/S/YIDUF">Yidu Tech Inc.</a> Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops

Yidu Tech Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10